RxDoctor Payments Data

Nawaf Murshed, MD

Neurology · Taylor, MINPI 1619102134

Payments from drug & device makers

$16,484in general payments, 2019–2025

Across 1,015 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$2K
  • AbbVie$2K
  • Novartis$2K
  • Biogen$1K
  • Livanova USA, Inc.$1K
  • Neurocrine Biosciences, Inc.$582
  • plus $9K from 54 others

What the payments were for

  • Speaking & faculty fees$911%
  • Travel & lodging$8105%
  • Food & beverage$15,55394%
  • Education$290%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.139$1,789
AbbVie(2 entities)101$1,686
Novartis109$1,503
Biogen77$1,150
Livanova USA, Inc.14$1,091
Neurocrine Biosciences, Inc.32$582
Amgen(2 entities)30$572
Pfizer30$491
Neurelis, Inc.30$480
Argenx US, Inc.24$478
EMD Serono, Inc.39$478
Sanofi25$459
Eisai Inc.27$457
Teva Pharmaceuticals USA, Inc.30$321
Bristol Myers Squibb21$321
Supernus Pharmaceuticals, Inc.27$314
SK Life Science, Inc.19$308
Lilly USA, LLC18$283
Genentech USA, Inc.24$265
Sunovion Pharmaceuticals Inc.18$238
CSL Behring12$197
Jazz Pharmaceuticals Inc.10$183
Lundbeck LLC8$171
AstraZeneca(2 entities)10$169
Acorda Therapeutics, Inc8$158
Amneal Pharmaceuticals LLC10$156
Sumitomo Pharma America, Inc.7$145
Catalyst Pharmaceuticals, Inc.7$134
MDD US Operations, LLC8$130
Vanda Pharmaceuticals Inc.4$110
Merz Pharmaceuticals, LLC5$109
Ipsen Biopharmaceuticals, Inc5$96
Johnson & Johnson4$93
Biohaven Pharmaceutical Holding Company Ltd.5$87
Alnylam Pharmaceuticals Inc.5$80
Upsher-smith Laboratories LLC5$78
Takeda Pharmaceuticals U.S.A., Inc.4$74
Adamas Pharmaceuticals, Inc.4$69
Acadia Pharmaceuticals Inc4$67
TG Therapeutics, Inc.3$65
Corium, LLC4$61
Merz North America, Inc.3$59
Aquestive Therapeutics, Inc.3$58
Akcea Therapeutics, Inc.3$52
Avanir Pharmaceuticals, Inc.3$49
Kyowa Kirin, Inc.3$45
Banner Life Sciences, LLC3$44
Aucta Pharmaceuticals, Inc.4$43
E.r. Squibb & Sons, L.L.C.3$42
Biohaven Pharmaceuticals, Inc.2$35
Aprecia Pharmaceuticals, LLC2$35
Bausch Health US, LLC2$33
Promius Pharma LLC2$31
Hospira, Inc.2$31
Xeris Pharmaceuticals, Inc.2$30
Amylyx Pharmaceuticals, Inc.2$27
Impel Pharmaceuticals Inc.1$24
Octapharma USA, Inc.1$24
Mallinckrodt Enterprises LLC1$20
Otsuka America Pharmaceutical, Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,484 in reported general payments places this provider in the 75th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$603,814
Medicare patients
543
Services billed
15,055

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab56$475,797
XywavSodium,calcium,mag,pot Oxybate13$213,422
Nurtec OdtRimegepant Sulfate176$206,596
FingolimodFingolimod Hcl12$106,778
UbrelvyUbrogepant71$85,627
IngrezzaValbenazine Tosylate11$84,977
BriviactBrivaracetam50$76,158
Dihydroergotamine Mesylate64$72,987
EpidiolexCannabidiol (Cbd)15$69,274
Aimovig AutoinjectorErenumab-Aooe60$56,244
AptiomEslicarbazepine Acetate28$55,940
QuliptaAtogepant41$46,041
NeuproRotigotine35$45,093
FycompaPerampanel31$43,773
Topiramate ErTopiramate67$39,972

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$491$206,596176 claims
AbbVieUbrelvy, Qulipta$1,686$131,669112 claims
UCB, Inc.Briviact, Neupro$1,789$121,25085 claims
Neurocrine Biosciences, Inc.Ingrezza$582$84,97711 claims
Sunovion Pharmaceuticals Inc.Aptiom$238$55,94028 claims
Eisai Inc.Fycompa$457$43,77331 claims
Neurelis, Inc.Valtoco$480$29,01033 claims
Upsher-smith Laboratories LLCZembrace Symtouch, Topiramate$78$27,313426 claims
Lilly USA, LLCReyvow$283$15,41317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 652 neurology providers in Michigan.

Other neurology in Taylor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →